- Home
- PULM vs EVAX Comparison
PULM vs EVAX Comparison
Compare PULM & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- EVAX
- Stock Information
- Founded
- PULM 2003
- EVAX 2008
- Country
- PULM United States
- EVAX Denmark
- Employees
- PULM N/A
- EVAX N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PULM Health Care
- EVAX Health Care
- Exchange
- PULM Nasdaq
- EVAX Nasdaq
- Market Cap
- PULM 18.3M
- EVAX 17.8M
- IPO Year
- PULM N/A
- EVAX 2021
- Fundamental
- Price
- PULM $4.89
- EVAX $2.93
- Analyst Decision
- PULM
- EVAX Strong Buy
- Analyst Count
- PULM 0
- EVAX 2
- Target Price
- PULM N/A
- EVAX $10.00
- AVG Volume (30 Days)
- PULM 9.6K
- EVAX 68.5K
- Earning Date
- PULM 11-07-2025
- EVAX 10-30-2025
- Dividend Yield
- PULM N/A
- EVAX N/A
- EPS Growth
- PULM N/A
- EVAX N/A
- EPS
- PULM N/A
- EVAX N/A
- Revenue
- PULM $369,000.00
- EVAX $3,176,000.00
- Revenue This Year
- PULM N/A
- EVAX N/A
- Revenue Next Year
- PULM $134.88
- EVAX $425.50
- P/E Ratio
- PULM N/A
- EVAX N/A
- Revenue Growth
- PULM N/A
- EVAX 1042.45
- 52 Week Low
- PULM $1.96
- EVAX $1.20
- 52 Week High
- PULM $10.40
- EVAX $16.69
- Technical
- Relative Strength Index (RSI)
- PULM 45.65
- EVAX 51.89
- Support Level
- PULM $4.70
- EVAX $2.81
- Resistance Level
- PULM $5.19
- EVAX $3.04
- Average True Range (ATR)
- PULM 0.15
- EVAX 0.21
- MACD
- PULM 0.07
- EVAX -0.00
- Stochastic Oscillator
- PULM 44.44
- EVAX 68.64
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.